Epigenetic regulation of miRNA genes in acute leukemia

Leukemia

Volumn 26, Issue 3, 2012, Pages 395-403

  Agirre, X ^a   Martinez Climent J A ^a   Odero, M D ^a   Prosper F ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

acute leukemia; epigenetic; miRNA

Indexed keywords

BIOLOGICAL MARKER; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DNA; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; HISTONE; HISTONE DEACETYLASE; MICRORNA; POLYCOMB GROUP PROTEIN; TRANSCRIPTION FACTOR E2F1; ZEBULARINE;

ACUTE LEUKEMIA; CELL DIFFERENTIATION; CELL PROLIFERATION; CHILDHOOD LEUKEMIA; DIAGNOSTIC VALUE; DNA METHYLATION; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; LEUKEMIA CELL; LEUKEMOGENESIS; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 84858000741     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.344     Document Type: Review

References (127)

1. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5: 522-531. (Pubitemid 38868508)
2. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-854. (Pubitemid 24014542)
3. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
4. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269.
5. Shivdasani RA. MicroRNAs: regulators of gene expression and cell differentiation. Blood 2006; 108: 3646-3653. (Pubitemid 44864540)
6. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004; 303: 83-86. (Pubitemid 38055775)
7. Georgantas 3rd RW, Hildreth R, Morisot S, Alder J, Liu CG, Heimfeld S et al. CD34+ hematopoietic stem-progenitor cell microRNA expression and function: A circuit diagram of differentiation control. Proc Natl Acad Sci USA 2007; 104: 2750-2755. (Pubitemid 46327951)
8. O'Connell RM, Chaudhuri AA, Rao DS, Gibson WS, Balazs AB, Baltimore D. MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output. Proc Natl Acad Sci USA 2010; 107: 14235-14240.
9. Chen CZ. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 2005; 353: 1768- 1771.
10. Aranda P, Agirre X, Ballestar E, Andreu EJ, Roman-Gomez J, Prieto I et al. Epigenetic signatures associated with different levels of differentiation potential in human stem cells. PLoS One 2009; 4: e7809.
11. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-15529. (Pubitemid 35403967)
12. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838. (Pubitemid 40839735)
13. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004. (Pubitemid 38327724)
14. Schotte D, Pieters R, Den Boer ML. MicroRNAs in acute leukemia: from biological players to clinical contributors. Leukemia 2011; e-pub ahead of print 24 June 2011; doi:10.1038/leu.2011.151.
15. Mi S, Lu J, Sun M, Li Z, Zhang H, Neilly MB et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci USA 2007; 104: 19971-19976.
16. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N et al. Pre-B cell proliferation and lymphoblastic leukemia/highgrade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA 2006; 103: 7024-7029.
17. Osada H, Takahashi T. MicroRNAs in biological processes and carcinogenesis. Carcinogenesis 2007; 28: 2-12. (Pubitemid 44942621)
18. Bandres E, Bitarte N, Arias F, Agorreta J, Fortes P, Agirre X et al. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res 2009; 15: 2281-2290.
19. Agirre X, Jimenez-Velasco A, San Jose-Eneriz E, Garate L, Bandres E, Cordeu L et al. Down-Regulation of hsa-miR-10a in Chronic Myeloid Leukemia CD34+ Cells Increases USF2-Mediated Cell Growth. Mol Cancer Res 2008; 6: 1830-1840.
20. Datta J, Kutay H, Nasser MW, Nuovo GJ, Wang B, Majumder S et al. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res 2008; 68: 5049-5058.
21. Grady WM, Parkin RK, Mitchell PS, Lee JH, Kim YH, Tsuchiya KD et al. Epigenetic silencing of the intronic microRNA hsa-miR- 342 and its host gene EVL in colorectal cancer. Oncogene 2008; 27: 3880-3888. (Pubitemid 351862055)
22. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setien F et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007; 67: 1424-1429. (Pubitemid 46383366)
23. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006; 9: 435-443. (Pubitemid 43832188)
24. Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N et al. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 2006; 5: 29.
25. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64: 3753-3756. (Pubitemid 38697282)
26. Balaguer F, Moreira L, Lozano JJ, Link A, Ramirez G, Shen Y et al. Colorectal cancers with microsatellite instability display unique miRNA profiles. Clin Cancer Res 2011; 17: 6239-6249.
27. Martens-Uzunova ES, Jalava SE, Dits NF, van Leenders GJ, Moller S, Trapman J et al. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene 2011; e-pub ahead of print 18 July 2011; doi:10.1038/ onc.2011.304.
28. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 2010; 11: 136-146.
29. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425-436. (Pubitemid 351185951)
30. San Jose-Eneriz E, Roman-Gomez J, Jimenez-Velasco A, Garate L, Martin V, Cordeu L et al. MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations. Mol Cancer 2009; 8: 69.
31. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009; 361: 1437-1447.
32. Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J et al. Upregulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 2011; 286: 19127-19137.
33. Lv SQ, Kim YH, Giulio F, Shalaby T, Nobusawa S, Yang H et al. Genetic Alterations in MicroRNAs in Medulloblastomas. Brain Pathol 2011; e-pub ahead of print 27 July 2011; doi:10.1111/ j.1750-3639.2011.00523.x.
34. Png KJ, Yoshida M, Zhang XH, Shu W, Lee H, Rimner A et al. MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev 2011; 25: 226-231.
35. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 2011; 16: 49-58.
36. Reichek JL, Duan F, Smith LM, Gustafson DM, O'Connor RS, Zhang C et al. Genomic and clinical analysis of amplification of the 13q31 chromosomal region in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Clin Cancer Res 2011; 17: 1463-1473.
37. Agueli C, Cammarata G, Salemi D, Dagnino L, Nicoletti R, La Rosa M et al. 14q32/miRNA clusters loss of heterozygosity in acute lymphoblastic leukemia is associated with up-regulation of BCL11a. Am J Hematol 2010; 85: 575-578.
38. Mavrakis KJ, Wolfe AL, Oricchio E, Palomero T, de Keersmaecker K, McJunkin K et al. Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat Cell Biol 2010; 12: 372-379.
39. Bousquet M, Quelen C, Rosati R, Mansat-De Mas V, La Starza R, Bastard C et al. Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med 2008; 205: 2499-2506.
40. Bandres E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 2009; 125: 2737-2743.
41. Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-Cespedes M, Blanco D et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 2008; 105: 13556-13561.
42. Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 2008; 68: 4123-4132.
43. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-692. (Pubitemid 46273572)
44. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16: 6-21. (Pubitemid 34049633)
45. Fernandez AF, Assenov Y, Martin-Subero JI, Balint B, Siebert R, Taniguchi H et al. A DNA methylation fingerprint of 1628 human samples. Genome Res 2011; e-pub ahead of print 12 July 2011.
46. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16: 168- 174.
47. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148-1159.
48. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-428. (Pubitemid 34587077)
49. Ting AH, McGarvey KM, Baylin SB. The cancer epigenome-components and functional correlates. Genes Dev 2006; 20: 3215-3231.
50. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 6: 107-116. (Pubitemid 43361543)
51. Esteller M. Cancer epigenomics: DNA methylomes and histonemodification maps. Nat Rev Genet 2007; 8: 286-298. (Pubitemid 46439286)
52. Roman-Gomez J, Cordeu L, Agirre X, Jimenez-Velasco A, San Jose-Eneriz E, Garate L et al. Epigenetic regulation of Wntsignaling pathway in acute lymphoblastic leukemia. Blood 2007; 109: 3462-3469. (Pubitemid 46572536)
53. Agirre X, Roman-Gomez J, Jimenez-Velasco A, Garate L, Montiel- Duarte C, Navarro G et al. ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia. Oncogene 2006; 25: 1862-1870.
54. San Jose-Eneriz E, Agirre X, Roman-Gomez J, Cordeu L, Garate L, Jimenez-Velasco A et al. Downregulation of DBC1 expression in acute lymphoblastic leukaemia is mediated by aberrant methylation of its promoter. Br J Haematol 2006; 134: 137-144. (Pubitemid 43893905)
55. Stumpel DJ, Schneider P, van Roon EH, Boer JM, de Lorenzo P, Valsecchi MG et al. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. Blood 2009; 114: 5490-5498.
56. Milani L, Lundmark A, Kiialainen A, Nordlund J, Flaegstad T, Forestier E et al. DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. Blood 2010; 115: 1214-1225.
57. Davidsson J, Lilljebjorn H, Andersson A, Veerla S, Heldrup J, Behrendtz M et al. The DNA methylome of pediatric acute lymphoblastic leukemia. Hum Mol Genet 2009; 18: 4054-4065.
58. Alvarez S, Suela J, Valencia A, Fernandez A, Wunderlich M, Agirre X et al. DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. PLoS One 2010; 5: e12197.
59. Lugthart S, Figueroa ME, Bindels E, Skrabanek L, Valk PJ, Li Y et al. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood 2010; 117: 234-241.
60. Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010; 17: 13-27.
61. Martin-Subero JI, Ammerpohl O, Bibikova M, Wickham-Garcia E, Agirre X, Alvarez S et al. A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS One 2009; 4: e6986.
62. Zhao H, Wang D, Du W, Gu D, Yang R. MicroRNA and leukemia: tiny molecule, great function. Crit Rev Oncol Hematol 2010; 74: 149-155.
63. Fabbri M, Croce CM. Role of microRNAs in lymphoid biology and disease. Curr Opin Hematol 2011; 18: 266-272.
64. Fulci V, Colombo T, Chiaretti S, Messina M, Citarella F, Tavolaro S et al. Characterization of B- and T-lineage acute lymphoblastic leukemia by integrated analysis of MicroRNA and mRNA expression profiles. Genes Chromosomes Cancer 2009; 48: 1069-1082.
65. Schotte D, De Menezes RX, Moqadam FA, Khankahdani LM, Lange-Turenhout E, Chen C et al. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica 2011; 96: 703-711.
66. Schotte D, Chau JC, Sylvester G, Liu G, Chen C, van der Velden VH et al. Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. Leukemia 2009; 23: 313- 322.
67. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008; 111: 3183-3189.
68. Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA 2008; 105: 15535-15540.
69. Taylor KH, Pena-Hernandez KE, Davis JW, Arthur GL, Duff DJ, Shi H et al. Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia. Cancer Res 2007; 67: 2617-2625. (Pubitemid 46548948)
70. Kuang SQ, Bai H, Fang ZH, Lopez G, Yang H, Tong W et al. Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia. Blood 2010; 115: 2412-2419.
71. Weber B, Stresemann C, Brueckner B, Lyko F. Methylation of human microRNA genes in normal and neoplastic cells. Cell Cycle 2007; 6: 1001-1005. (Pubitemid 46708569)
72. Roman-Gomez J, Agirre X, Jimenez-Velasco A, Arqueros V, Vilas- Zornoza A, Rodriguez-Otero P et al. Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. J Clin Oncol 2009; 27: 1316-1322.
73. Martin-Palanco V, Rodriguez G, Martin C, Rojas R, Torres A, Roman-Gomez J. microRNA methylation profile has prognosis impact in acute lymphoblastic leukemia patients undergoing stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 745-748.
74. Agirre X, Vilas-Zornoza A, Jimenez-Velasco A, Martin-Subero JI, Cordeu L, Garate L et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res 2009; 69: 4443-4453.
75. Rodriguez-Otero P, Roman-Gomez J, Vilas-Zornoza A, Jose- Eneriz ES, Martin-Palanco V, Rifon J et al. Deregulation of FGFR1 and CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the MIR9 family. Br J Haematol 2011; 155: 73-83.
76. Wong KY, So CC, Loong F, Chung LP, Lam WW, Liang R et al. Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS One 2011; 6: e19027.
77. Vilas-Zornoza A, Agirre X, Martin-Palanco V, Martin-Subero JI, San Jose-Eneriz E, Garate L et al. Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in acute lymphoblastic leukemia. PLoS One 2011; 6: e17012.
78. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447: 1130-1134. (Pubitemid 47014436)
79. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26: 745-752. (Pubitemid 46856245)
80. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007; 26: 731-743. (Pubitemid 46856247)
81. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE et al. p53-mediated activation of miRNA34 candidate tumorsuppressor genes. Curr Biol 2007; 17: 1298-1307. (Pubitemid 47176893)
82. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 2007; 67: 8433-8438. (Pubitemid 47437414)
83. Agirre X, Novo FJ, Calasanz MJ, Larrayoz MJ, Lahortiga I, Valganon M et al. TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia. Mol Carcinog 2003; 38: 201-208. (Pubitemid 37523712)
84. Chim CS, Wong KY, Qi Y, Loong F, Lam WL, Wong LG et al. Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis 2010; 31: 745-750.
85. Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol 2005; 23: 6306-6315. (Pubitemid 46218840)
86. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30: 41-47.
87. Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 1998; 91: 3995-4019. (Pubitemid 28261960)
88. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535-1548.
89. Li S, Ilaria Jr RL, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999; 189: 1399-1412. (Pubitemid 29227526)
90. Bueno MJ, Perez de Castro I, Gomez de Cedron M, Santos J, Calin GA, Cigudosa JC et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 2008; 13: 496-506. (Pubitemid 351763902)
91. Chim CS, Wong KY, Leung CY, Chung LP, Hui PK, Chan SY et al. Epigenetic inactivation of the hsa-miR-203 in haematological malignancies. J Cell Mol Med 2011; e-pub ahead of print 15 February 2011; doi:10.1111/j.1582- 4934.2011.01274.x.
92. Pui CH, Behm FG, Downing JR, Hancock ML, Shurtleff SA, Ribeiro RC et al. 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol 1994; 12: 909-915.
93. Stumpel DJ, Schotte D, Lange-Turenhout EA, Schneider P, Seslija L, de Menezes RX et al. Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale. Leukemia 2011; 25: 429-439.
94. Dou L, Zheng D, Li J, Li Y, Gao L, Wang L et al. Methylationmediated repression of microRNA-143 enhances MLL-AF4 oncogene expression. Oncogene 2011; e-pub ahead of print 27 June 2011; doi:10.1038/onc.2011.248.
95. Schotte D, Lange-Turenhout EA, Stumpel DJ, Stam RW, Buijs- Gladdines JG, Meijerink JP et al. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia. Haematologica 2010; 95: 1675-1682.
96. Bhatia S, Kaul D, Varma N. Potential tumor suppressive function of miR-196b in B-cell lineage acute lymphoblastic leukemia. Mol Cell Biochem 2010; 340: 97-106.
97. Li X, Liu J, Zhou R, Huang S, Chen XM. Gene silencing of MIR22 in acute lymphoblastic leukaemia involves histone modifications independent of promoter DNA methylation. Br J Haematol 2010; 148: 69-79.
98. Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res 2011; 17: 2613-2618.
99. Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci USA 2010; 107: 20980-20985.
100. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 2007; 39: 237-242.
101. Calvanese V, Horrillo A, Hmadcha A, Suarez-Alvarez B, Fernandez AF, Lara E et al. Cancer genes hypermethylated in human embryonic stem cells. PLoS One 2008; 3: e3294.
102. Martin-Subero JI, Kreuz M, Bibikova M, Bentink S, Ammerpohl O, Wickham-Garcia E et al. New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood 2009; 113: 2488-2497.
103. Cao Q, Mani RS, Ateeq B, Dhanasekaran SM, Asangani IA, Prensner JR et al. Coordinated Regulation of Polycomb Group Complexes through microRNAs in Cancer. Cancer Cell 2011; 20: 187-199.
104. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 2006; 125: 301-313. (Pubitemid 44313811)
105. Danen-van Oorschot AA, Kuipers JE, Arentsen-Peters S, Schotte D, de Haas V, Trka J et al. Differentially expressed miRNAs in cytogenetic and molecular subtypes of pediatric acute myeloidleukemia. Pediatr Blood Cancer 2011; e-pub ahead of print 4 August 2011; doi:10.1002/pbc.23279.
106. Havelange V, Stauffer N, Heaphy CC, Volinia S, Andreeff M, Marcucci G et al. Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling. Cancer 2011; e-pub ahead of print 31 March 2011; doi:10.1002/cncr.26096.
107. Schwind S, Maharry K, Radmacher MD, Mrozek K, Holland KB, Margeson D et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28: 5257-5264.
108. Marcucci G, Radmacher MD, Maharry K, Mrozek K, Ruppert AS, Paschka P et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1919-1928. (Pubitemid 351620112)
109. Marcucci G, Mrozek K, Radmacher MD, Garzon R, Bloomfield CD. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 2011; 117: 1121-1129.
110. Vazquez I, Maicas M, Marcotegui N, Conchillo A, Guruceaga E, Roman-Gomez J et al. Silencing of hsa-miR-124 by EVI1 in cell lines and patients with acute myeloid leukemia. Proc Natl Acad Sci USA 2010; 107: E167-E168; author reply E169-170.
111. Hackanson B, Bennett KL, Brena RM, Jiang J, Claus R, Chen SS et al. Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. Cancer Res 2008; 68: 3142-3151.
112. Dickstein J, Senyuk V, Premanand K, Laricchia-Robbio L, Xu P, Cattaneo F et al. Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome. Proc Natl Acad Sci USA 2010; 107: 9783-9788.
113. Vazquez I, Maicas M, Cervera J, Agirre X, Marin-Bejar O, Marcotegui N et al. Downregulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia. Haematologica 2011; 96: 1448-1456.
114. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, van der Poel-van de Luytgaarde S, Hack R et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 2003; 101: 837-845.
115. Haas K, Kundi M, Sperr WR, Esterbauer H, Ludwig WD, Ratei R et al. Expression and prognostic significance of different mRNA 5′-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration. Genes Chromosomes Cancer 2008; 47: 288-298. (Pubitemid 351323758)
116. Lugthart S, van Drunen E, van Norden Y, van Hoven A, Erpelinck CA, Valk PJ et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 2008; 111: 4329-4337.
117. Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010; 31: 766-776.
118. Koschmieder S, Halmos B, Levantini E, Tenen DG. Dysregulation of the C/EBPalpha differentiation pathway in human cancer. J Clin Oncol 2009; 27: 619-628.
119. Mueller BU, Pabst T. C/EBPalpha and the pathophysiology of acute myeloid leukemia. Curr Opin Hematol 2006; 13: 7-14.
120. Pulikkan JA, Dengler V, Peramangalam PS, Peer Zada AA, Muller-Tidow C, Bohlander SK et al. Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood 2010; 115: 1768- 1778.
121. Eyholzer M, Schmid S, Schardt JA, Haefliger S, Mueller BU, Pabst T. Complexity of miR-223 regulation by CEBPA in human AML. Leuk Res 2010; 34: 672-676.
122. Fazi F, Racanicchi S, Zardo G, Starnes LM, Mancini M, Travaglini L et al. Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. Cancer Cell 2007; 12: 457-466. (Pubitemid 350046404)
123. Paschka P, Marcucci G, Ruppert AS, Mrozek K, Chen H, Kittles RA et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006; 24: 3904- 3911.
124. Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood 2010; 115: 2372-2379.
125. Gao XN, Lin J, Li YH, Gao L, Wang XR, Wang W et al. MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia. Oncogene 2010; 30: 3416-3428.
126. Cheng JC, Kinjo K, Judelson DR, Chang J, Wu WS, Schmid I et al. CREB is a critical regulator of normal hematopoiesis and leukemogenesis. Blood 2008; 111: 1182-1192. (Pubitemid 351213399)
127. Pigazzi M, Manara E, Baron E, Basso G. miR-34b targets cyclic AMP-responsive element binding protein in acute myeloid leukemia. Cancer Res 2009; 69: 2471-2478.